title: Duct-narrowing chronic pancreatitis without immunoserologic abnormality: comparison with duct-narrowing chronic pancreatitis with positive serological evidence and its clinical management.
abstract: We reviewed the clinical features and clinical course of patients with duct-narrowing chronic pancreatitis who were negative for immunoserologic test results (n = 16) in comparison with the findings for serological test-positive patients (n = 20) in order to determine an adequate treatment for those who had typical morphology of autoimmune pancreatitis in the absence of immunoserologic abnormality. No significant differences were found between the two groups of patients in clinical profiles including associated autoimmune-related diseases, pancreatic histology, and response to steroid therapy. Of the seronegative patients, eight who showed an improvement in narrowing of the main pancreatic duct with steroid therapy and three who did no show an improvement or who relapsed after surgical resection without this therapy had stenosis of the common bile duct with increased levels of serum hepatobiliary enzymes, except for two patients with affected sites limited to the body or tail of the gland. For the remaining five patients, who showed an improvement in pancreatic duct changes or long-term remission after surgery without steroid administration, normal biochemistry test results for liver functions were obtained, with no abnormal cholangiographic findings in the three patients examined. Duct-narrowing chronic pancreatitis without immunoserologic abnormality overlaps in clinical features with that fulfilling the immunoserologic criteria for a diagnosis of autoimmune pancreatitis. In particular, the disease with bile duct involvement should be treated clinically as autoimmune pancreatitis, for which steroid therapy is recommended, even if an autoimmune mechanism is not demonstrated serologically.
authors.affiliation: Department of Gastroenterology and Surgery, Saisekai Kanazawa Hospital, Akatsuchi-machi Ni, Kanazawa, Japan. fujiko@po.incl.ne.jp
authors.forename: Tokio
authors.initials: T
authors.lastname: Wakabayashi
authors.forename: Yukimitsu
authors.initials: Y
authors.lastname: Kawaura
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Satomura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Urabe
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Watanabe
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Motoo
authors.forename: Norio
authors.initials: N
authors.lastname: Sawabu
mesh_terms: D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood; D001327:Autoimmune Diseases / Q000097:blood* / Q000175:diagnosis* / Q000628:therapy; D016022:Case-Control Studies; D002908:Chronic Disease; D003251:Constriction, Pathologic / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D010183:Pancreatic Ducts; D010195:Pancreatitis / Q000097:blood* / Q000175:diagnosis* / Q000628:therapy; D016896:Treatment Outcome; D005719:gamma-Globulins / Q000378:metabolism
chemical_list: D000974:Antibodies, Antinuclear; D007074:Immunoglobulin G; D005719:gamma-Globulins